Patients must be able to swallow tablets whole
Patients must be able to swallow tablets or capsules; a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible
Patients must be able to swallow tablets
Patients must be able to swallow tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow tablets
Participants must be able to swallow ribociclib capsules or tablets
Must be able to swallow ribociclib and everolimus capsules/tablets
Must be able to swallow LEE011 and everolimus capsules/tablets
Patients must be able to swallow tablets (or applesauce, if part of bioavailability \crushed\ six patient cohort)
Able to swallow tablets.
Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy tube (G-tube) administration is not allowed
Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy tube (G-tube) administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed
Participant must be able to swallow tablets or capsules. A participant with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible.
Patients must be able to swallow intact tablets
Patients who are not able to swallow intact tablets are not eligible
Has an inability to swallow tablets or capsules
Able to swallow bicalutamide and ribociclib capsules/tablets.
Be able to swallow tablets.
Are able to swallow capsules and tablets.
Patients must be able to swallow intact tablets; patients who cannot swallow intact tablets are not eligible
Able to swallow the study drugs whole as tablets
Patients must be able to swallow whole tablets
CAPMATINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
CERITINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
REGORAFENIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
ENTRECTINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
Patient has a condition that would prevent him or her from being able to swallow Toca FC tablets or absorb flucytosine.
Inability to swallow tablets or capsules
Part E: Are able to swallow capsules or tablets
The subject must be able to swallow tablets, or receive tablets crushed and/or dispensed in water via nasogastric or orogastric tube.
Patients must be able to swallow tablets and have no significant impairment in gastrointestinal absorption
Patients who are not able to swallow capsules or tablets
Must be able to swallow ribociclib and tamoxifen capsules/tablets
Patients must be able to swallow tablets whole
Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy (G)-tube administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed
Patients must be able to swallow capsules/tablets
Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
For subjects to be enrolled in Cohort 4: Able to swallow and retain orally administered tablets
Are able to swallow capsules and tablets.
Must be able to swallow ribociclib / placebo capsules/tablets
Inability to swallow tablets or capsules
Able to swallow tablets
Patients must be willing and able to swallow oral tablets
Are able to swallow tablets
Patients must be able to swallow tablets
Patients with an inability to swallow tablets or capsules
Are able to swallow capsules or tablets
Patients must be able to swallow tablets
Able to swallow tablets
Ability to swallow intact palbociclib capsules and bicalutamide tablets
Patients must be able to swallow whole tablets (for MK-2206); nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
Patients who are not able to swallow capsules or tablets
Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
Patients must be able to swallow tablets whole, without crushing
Patients must be able to swallow whole tablets; tablets must not be crushed or chewed
Patients must be able to swallow whole tablets and capsules
Patient must be able to swallow whole tablets
Patients must be able to swallow tablets
Patients must be able to swallow tablets
Must be able to swallow tablets and capsules
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients must be able to swallow intact capsules/tablets, unless otherwise specified in the subprotocol to which they are assigned
Subjects must be able to swallow capsules/tablets
Patients must be able to swallow whole tablets or capsules; nasogastric or g-tube administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed